PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 70 | 133–142
Article title

Evaluation of bone metabolism in obese men and women with metabolic syndrome

Content
Title variants
PL
Wpływ zespołu metabolicznego na metabolizm kości otyłych mężczyzn i kobiet
Languages of publication
EN
Abstracts
EN
BACKGROUND: It was suggested that metabolic syndrome (MS) is an additional risk factor that increases the risk of osteoporotic fractures. The aim of this study was to evaluate the impact of metabolic syndrome on bone metabolism and the risk of osteoporotic fracture in obese men and women. MATERIALS AND METHODS: The study involved 40 obese men and 40 obese women, divided into 2 subgroups: patients without MS (20 men and 20 women); and patients with MS (20 men and 20 women). The serum levels of PTH, 25-OH-D3, CTX1, osteocalcin, FGF23, total Ca and P were determined. The total absolute fracture risk was estimated using the Fracture Risk Assessment Tool. The control group consisted of 15 normal body mass, healthy men and women similar in age. RESULTS: Obese women with MS have a higher risk of osteoporotic fractures (3.0 vs. 1.6%; p < 0.001) and serum levels of phosphorus (1.8 vs. 1.12 mmol/l; p < 0.001) but lower 25(OH)D3 (7.3 vs. 34.6 ng/ml; p < 0.01) than obese women without MS. There were no differences in the risk of osteoporotic fracture or other study parameters between obese men with and without MS. Women with MS had lower serum CTX1 levels (0.27 ng/ml vs. 0.41 ng/ml; p < 0.05) than men. CONCLUSIONS: Metabolic syndrome does not influence the selected parameters of bone metabolism in either men or women. However, women with metabolic syndrome have lower serum 25-OH-D3 levels. Women, but not men with metabolic syndrome have a higher 10-year absolute fracture risk than obese women with-out metabolic syndrome.
PL
WSTĘP: Wydaje się, że zespół metaboliczny (MS) jest dodatkowym czynnikiem zwiększającym ryzyko złamań osteoporotycznych. Celem tego badania była ocena wpływu zespołu metabolicznego na metabolizm kości i ryzyko złamań osteoporotycznych u otyłych mężczyzn i kobiet. MATERIAŁ I METODY: W badaniu wzięło udział 40 otyłych mężczyzn i 40 otyłych kobiet. Badanych podzielono na 2 grupy: pacjentów z otyłością bez MS (20 mężczyzn i 20 kobiet) i pacjentów z MS (20 mężczyzn i 20 kobiet). W grupach badanych oznaczono w surowicy stężenie parathormonu (PTH), 25-OH-D3, C-końcowego usieciowanego peptydu kolagenu typu 1 (CTX1), osteokalcyny, FGF23, wapnia (Ca) i fosforu (P). Ryzyko złamania osteoporotycznego oszacowano, stosując skalę FRAX (Fracture Risk Assessmen Tool). Grupę kontrolną stanowiło 15 zdrowych mężczyzn i kobiet w podobnym wieku. WYNIKI: Otyłe kobiety z MS charakteryzowały się większym ryzykiem złamań osteoporotycznych (3,0 vs 1,6%; p < 0,001), stężeniem w surowicy fosforu (1,8 vs 1,12 mmol/l; p < 0,001) oraz mniejszym stężeniem 25-OH-D3 (7,3 vs 34,6 ng/ml; p < 0,01) w porównaniu z kobietami bez MS. Nie stwierdzono istotnych różnic w ryzyku złamań osteoporotycznych i stężeniach ocenianych parametrów między mężczyznami z otyłością bez MS i z MS. Kobiety z MS miały niższe stężenie CTX-1 (0,27 ng/ml vs. 0,41 ng/ml; p) w porównaniu z mężczyznami. WNIOSKI: Zespół metaboliczny nie wpływa na wskaźniki metabolizmu kostnego u mężczyzn i kobiet. Kobiety z zespołem metabolicznym charakteryzują się jednak mniejszym stężeniem 25-OH-D3. Kobiety, ale nie mężczyźni, z zespołem metabolicznym, wykazują większe 10-letnie ryzyko złamania osteoporotycznego niż kobiety z otyłością bez zespołu metabolicznego.
Year
Volume
70
Pages
133–142
Physical description
References
  • 1. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004; 89: 2548–2556.
  • 2. Stefanska A., Bergmann K., Sypniewska G. Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance. Adv. Clin. Chem. 2015; 72: 1–75.
  • 3. von Muhlen D., Safii S., Jassal S.K., Svartberg J., Barrett-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int 2007; 18: 1337–1344.
  • 4. Szulc P., Varennes A., Delmas P.D., Goudable J., Chapurlat R. Men with metabolic syndrome have lower bone mineral density but lower fracture risk—the MINOS study. J. Bone Miner. Res. 2010; 25: 1446–1454.
  • 5. Leve A.S., Stevens L.A., Schmid C.H. Zhang Y.L., Castro A.F. 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J. A new equation to estimate glomerular filtration rate. Ann. Int. Med. 2009; 150(9): 604–612.
  • 6. Zhao L.J., Jiang H., Papasian C.J., Maulik D., Drees B., Hamilton J., Deng H.W. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J. Bone Miner. Res. 2008; 23: 17–29.
  • 7. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2006; 2: 35–43.
  • 8. García-Martín A., Cortés-Berdonces M., Luque-Fernández I., Rozas-Moreno P., Quesada-Charneco M., Muñoz-Torres M. Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. Menopause 2011; 18: 537–541.
  • 9. Reinehr T., Roth C.L. A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss. Int. J. Obes. 2010; 34: 852–858.
  • 10. Bezerra dos Santos Magalhães K., Magalhães M.M., Diniz E.T., Lucena C.S., Griz L., Bandeira F. Metabolic syndrome and central fat distribution are related to lower serum osteocalcin concentrations. Ann. Nutr. Metab. 2013; 62: 183–188.
  • 11. Cifuentes M., Johnson M.A., Lewis R.D., Heymsfield S.B., Chowdhury H.A., Modlesky C.M., Shapses S.A. Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int. 2003; 14: 116–122.
  • 12. Papakitsou E.F., Margioris A.N., Dretakis K.E., Trovas G., Zoras U., Lyritis G., Dretakis E.K., Stergiopoulos K. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 2004; 47: 185–193.
  • 13. Kobielski A. Czynność osi somatotropinowej, system OPG/sRANL a gęstość mineralna kości i metabolizm kostny u otyłych kobiet po menopauzie. Rozprawa doktorska. Śląski Uniwersytet Medyczny. Katowice 2008.
  • 14. Ford E.S., Ajani U.A., McGuire L.C., Liu S. Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 2005; 28: 1228–1230.
  • 15. Lu L., Yu Z., Pan A., Hu F.B., Franco O.H., Li H., Li X., Yang X., Chen Y., Lin X. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009; 32: 1278–1283.
  • 16. Hyppönen E., Boucher B.J., Berry D.J., Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298–305.
  • 17. Reis J.P., von Mühlen D., Miller E.R. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur. J. Endocrinol. 2008; 159: 41–48.
  • 18. McGill A.T., Stewart J.M., Lithander F.E., Strik C.M., Poppitt S.D. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr. J. 2008; 7: 4.
  • 19. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 2004; 79: 820–825.
  • 20. Norman A.W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542–5548.
  • 21. Reusch J.E., Begum N., Sussman K.E., Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991; 129: 3269–3273.
  • 22. Worrall D.S., Olefsky J.M. The effects of intracellular calcium depletion on insulin signaling in 3T3-L1 adipocytes. Mol. Endocrinol. 2002; 16: 378–389.
  • 23. Zemel M.B., Shi H., Greer B., Dirienzo D., Zemel P.C. Regulation of adiposity by dietary calcium. FASEB J. 2000; 14: 1132–1138.
  • 24. Shi H., Norman A.W., Okamura W.H., Sen A., Zemel M.B. 1 alpha, 25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nonge-nomic action. FASEB J. 2001; 15: 2751–2753.
  • 25. Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005; 28: 2926–2932.
  • 26. Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi F. Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. Am. J. Clin. Nutr. 2005; 82: 523–530.
  • 27. Zemel M.B., Richards J., Mathis S., Milstead A., Gebhardt L., Silva E. Dairy augmentation of total and central fat loss in obese subjects. Int. J. Obes. 2005; 29: 391–397.
  • 28. McCarty M.F., Thomas C.A. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med. Hypotheses 2003; 61: 535–542.
  • 29. Andersen T., McNair P., Fogh-Andersen N., Nielsen T.T., Hyldstrup L., Transbøl I. Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity. Metabolism1986; 35: 147–151.
  • 30. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B. Sr., Gaziano J.M., Vasan R.S. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Int. Med. 2007; 167: 879–885.
  • 31. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627–2633.
  • 32. de Boer I.H., Rue T.C., Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 2009; 53: 399–407.
  • 33. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Jüppner H., Lee H., Finkelstein J.S. Regulation of C‐terminal and intact FGF‐23 by dietary phosphate in men and women. J. Bone Miner. Res. 2006; 21: 1187–1196.
  • 34. Larsson T., Nisbeth U., Ljunggren Ö., Jüppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272–2279.
  • 35. Ribot C., Tremollieres F., Pouilles J.M., Bonneu M., Germain F., Louvet J.P. Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone 1987; 8: 327–331.
  • 36. Reid I.R., Ames R., Evans M.C., Sharpe S., Gamble G., France J.T., Li T.M., Cundy T.F. Determinants of total body and regional bone mineral density in normal postmenopausal women – a key role for fat mass. J. Clin. Endocrinol. Metab. 1992; 75: 45–51.
  • 37. Reid I.R. Relationships among body mass, its components, and bone. Bone 2002; 31: 547–555.
  • 38. Reid I.R., Plank L.D., Evans M.C. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J. Clin. Endocrinol. Metab. 1992; 75: 779–782.
  • 39. Thomas T., Burguera B., Melton L., Atkinson E.J., O'Fallon W.M., Riggs B.L., Khosla S. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29: 114–120.
  • 40. De Laet C., Kanis J.A., Odén A., Johanson H., Johnell O., Delmas P., Eisman J.A., Kroger H., Fujiwara S., Garnero P., McCloskey E.V., Mellstrom D., Melton L.J. 3rd, Meunier P.J., Pols H.A., Reeve J., Silman A., Tenenhouse A. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005; 16: 1330–1338.
  • 41. Premaor M.O., Pilbrow L., Tonkin C., Parker R.A., Compston J. Obesity and fractures in postmenopausal women. J. Bone Miner. Res. 2010; 25: 292–297.
  • 42. Schuit S.C.E., van der Klift M., Weel A.E.A.M., de Laet C.E., Burger H., Seeman E., Hofman A., Uitterlinden A.G., van Leeuwen J.P., Pols H.A. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195–202.
  • 43. Kanis J.A., Johnell O., Odén A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19: 385–397.
  • 44. Hwang D.K., Choi H.J. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int. 2010; 21: 425–431.
  • 45. Ahmed L.A., Schirmer H., Berntsen G.K., Fønnebø V., Joakimsen R.M. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromsø study. Osteoporos Int. 2006; 17: 426–432.
  • 46. Cao J.J. Effects of obesity on bone metabolism. J. Orthop. Surg. Res. 2011; 6: 30–36.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-9e762191-f873-4cb1-bedf-bc6fb74f6cbf
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.